Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.
about
Blood CEA levels for detecting recurrent colorectal cancerBlood CEA levels for detecting recurrent colorectal cancerMeta-analysis of colorectal cancer follow-up after potentially curative resectionSurveillance and Survivorship after Treatment for Colon CancerFollow-up strategies for patients treated for non-metastatic colorectal cancer.Does finding early recurrence improve outcomes, and at what cost?Optimizing adjuvant therapy and survivorship care of stage III colon cancer.CT colonography for surveillance of patients with colorectal cancer: Systematic review and meta-analysis of diagnostic efficacy.Nomograms for predicting the prognostic value of serological tumor biomarkers in colorectal cancer patients after radical resectionTailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations.Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review.The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer.Follow-up after curative treatment for colorectal cancer: longitudinal evaluation of patient initiated follow-up in the first 12 months.Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer.Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.History and present status of pulmonary metastasectomy in colorectal cancer.Propensity score matching: a conceptual review for radiology researchersSurveillance for asymptomatic recurrence in resected stage III colon cancer: does it result in a more favorable outcome?Optimal delivery of colorectal cancer follow-up care: improving patient outcomes.Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel.Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEAPrognosis and postoperative genital function of function-preservative surgery of pelvic autonomic nerve preservation for male rectal cancer patients.Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival.The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trialCarbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement.The COLOFOL trial: study design and comparison of the study population with the source cancer populationDisparities in long-term radiographic follow-up after cystectomy for bladder cancer: Analysis of the SEER-Medicare databaseSymptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study.Clinically Meaningful Use of Blood Tumor Markers in Oncology.Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.Abdominosacral resection for locally recurring rectal cancer.Colorectal cancer surveillance: what's new and what's nextThe Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal CancerIntensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis.Lung metastasectomy paradoxes in practice: reflections on the Catania conference.Finding the evidence for pulmonary metastasectomy in colorectal cancer: the PulMicc trial.Cost Considerations in the Evaluation and Treatment of Colorectal Cancer.Management of resectable colorectal lung metastases.
P2860
Q24186921-195605FD-78FD-44B2-BD65-7D2662EC378FQ24194206-97F37241-2D56-4CCF-B9D9-92B31E9C3C71Q28069831-7CFCAD3A-0589-420F-A629-A7719F818194Q28088348-2B1F584F-4A10-4C15-8A75-613BF8245298Q30240736-AEE5B5F2-4F13-4B54-868D-ABF196BD8586Q30249096-F9D4FA01-92C4-4984-B43A-B1F9F10E7987Q30249616-ADA12A3F-2BD8-45A4-A005-B731649B06EBQ30251759-E1B4FE00-8F93-409B-891E-1B5B10E56A81Q33572453-963FE7E3-E151-4A81-BA3A-5495DBF7623CQ33574744-774D4BD6-7A17-4840-BFC5-3255B3BADD57Q33612653-9A0DD405-25BB-4009-9E22-DA6FA19DB444Q33629362-73C98C44-1045-4F7D-878F-60FA6255B9F2Q33729452-22AFF0FA-21EA-4E41-A088-9EB54C858780Q33912255-743B9BAB-2E6B-4851-A057-88ABC5F36340Q34251380-E6D7236B-99D8-4C0A-AB47-1582BFAECBA5Q34404960-9C853A32-772E-4F40-95CF-E8D54ECD91FFQ35140167-77BC02F9-BAB6-4D48-BDDA-9345BC36FC1DQ35419441-93769EB3-2972-4634-A9FC-6232D7A57CBEQ35654007-25616E86-5EC8-4D5D-B0B6-08C599AE58E6Q35884196-A4D3E7F0-3B44-49C4-875E-3826B3D747DAQ35945773-CC088D12-BA83-4CF0-86C9-F7B0B3CA35E4Q35955280-59072C5B-83D2-4908-B440-FCDD6DA5A040Q36223053-8BC8DAA4-6057-4F97-897B-319A2D2C65EAQ36272668-8D2786A2-0F01-4717-8F45-0D54E91EB61BQ36304168-E1185468-BDDF-4E56-9AD1-821B9D0C00A2Q36358540-DDFBE364-9DE4-470B-90A2-B1A2D5864525Q36400239-F2B61728-B68E-43DB-B8C0-26211DC1DB15Q36525588-8F24257E-8091-4D1E-A264-A9F6A793EA08Q36820842-4B14FCC2-2969-4B92-B976-0D1B626C37E8Q36905273-FF2979BE-77F3-4B5F-BE61-096AEDD95EC2Q37500722-119D644D-1570-47D7-A599-1CF277E250E5Q37524976-642DDA7E-0954-4E42-9C93-F061213AFA1AQ37531921-E60F5332-1D89-47B7-8AED-6CEDCCF8BE9BQ37602712-062D1E8B-E73A-427B-9159-EE739EA4AE9AQ37634006-4EA477B2-A656-4151-AA04-6E6A893DB8A7Q38269844-96E1DE51-F691-4945-AC3C-54E8EF031F24Q38348071-5ABD0401-403E-4FB8-A2BF-C87D88E324D6Q38348082-BD372CA9-B7CF-442D-86A2-FAC1FC622710Q38544945-5D6E6EBB-8DCE-4F01-9730-C50443F11F2FQ38667176-5A7A87F1-C1C4-4DD9-956F-C8CB0182F336
P2860
Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Effect of 3 to 5 years of sche ...... ACS randomized clinical trial.
@en
type
label
Effect of 3 to 5 years of sche ...... ACS randomized clinical trial.
@en
prefLabel
Effect of 3 to 5 years of sche ...... ACS randomized clinical trial.
@en
P2093
P356
P1476
Effect of 3 to 5 years of sche ...... ACS randomized clinical trial.
@en
P2093
Alice Fuller
Andrea Corkhill
David Mant
FACS Trial Investigators
Peter Rose
Rafael Perera
Steve George
P304
P356
10.1001/JAMA.2013.285718
P407
P577
2014-01-01T00:00:00Z